Winterlight Labs, Inc. Enters Collaboration With Johnson & Johnson Innovation To Develop A Digital Biomarker For Diagnosis Of Early Stage Alzheimer’s Disease

Toronto, Canada-based Winterlight Labs, Inc, (Winterlight) recently announced it has entered a partnership with Janssen Pharmaceuticals (Janssen) to develop a digital biomarker for the diagnosis of early stage Alzheimer’s Disease (AD). Janssen, which is part of Johnson & Johnson Innovation LLC, is a Belgium-based pharmaceutical company that conducts research and development activities related to a wide range of medical disorders.

Currently, Winterlight’s technology reports a 91% accuracy rating for distinguishing Alzheimer’s from healthy aging. It accomplishes this by utilizing AI to create digital biomarkers to evaluate a person’s speech and language. Through its collaboration . . .